Key facts
- Antiverse’s last known valuation is $3.0M (Nov 2020).
- It has raised $17.6M; the latest was Later Stage VC ($9.3M) in Mar 2026.
- Notable investors include Innovate UK, Tech Nation Group, SyndicateRoom, Future Planet Capital, Cambridge Angels — 34 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 34 names
- ·Watchlist + deal alerts for Antiverse
- ·The full record, as it builds
Funding rounds
No funding rounds for Antiverse are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Antiverse
Developer of a drug discovery platform designed to predict antibody-antigen binding and provide antibody drug candidates against difficult targets. The company's platform uses machine learning and cell-free protein synthesis to predict antibodies that bind to a given antigen target with high affinity, enabling pharma companies and contract research organizations to speed up antibody hit discovery.
- Sector
- Healthcare
- HQ
- Cardiff, United Kingdom
- Founded
- 2017
- Employees
- 28
- Website
- antiverse.io/
- Ownership
- Privately Held (backing)
Antiverse doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Antiverse shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Antiverse in its N-PORT filings yet. We sweep new filings monthly.